Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th
Malignant Peritoneal Mesothelioma
Explore 4 assets in Malignant Peritoneal Mesothelioma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Bayer
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03507452CT.gov First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Peritoneal Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th (this asset) | Bayer | P1 | CC · 47 |
| Atezolizumab | M.D. Anderson Cancer Center | P2 | CCC |
| Interferon Alfa-2B | David Bartlett | P1/2 | CCC |
| Celecoxib | David Bartlett | P1/2 | CCC |
| Methoxyamine | National Cancer Institute (NCI) | P1/2 | CCC |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P1/2 | CCC |
| Rintatolimod | David Bartlett | P1/2 | CC |
| Pegargiminase | Polaris Group | P1 | CC |
| ct-95 | Context Therapeutics Inc. | P1 | CC |
Other indications for Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pleural Epithelioid Mesothelioma | — | P1 | CC · 47 |
| Ovarian Serous Adenocarcinoma | — | P1 | CC · 47 |
| Pancreatic Ductal Adenocarcinoma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th in Malignant Peritoneal Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-mesothelin-human-monoclonal-mf-t-igg1-heavy-chain-disulfide-with-human-monoclonal-mf-t-igg1-lambda-chain-dimer-n6-4-4-3-bis2-12-dihydro-3-hydroxy-kappao-1-methyl-2-oxo-kappao-4-pyridinylcarbonylaminoethylamino-2-bis2-12-dihydro-3-hydroxy-kappao-1-methyl-2-oxo-kappao-4-pyridinylcarbonylaminoethylaminomethylpropylphenylamino-14-dioxobutyl-l-lysine-complex-with-thorium-227th-malignant-peritoneal-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →